Back to School: How biopharma can reboot drug development. Access exclusive analysis here
FDA approved an sNDA from Shire for Vyvanse lisdexamfetamine dimesylate as maintenance treatment of ADHD
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury